A sensitive radioimmunoprecipitation assay for assessing the clinical relevance of antibodies to IFN β

17Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

Background: Some multiple sclerosis (MS) patients treated with interferon beta (IFN β) develop antibodies to the drug. Neutralising antibody (NAB) assays for IFN β are expensive and the clinical relevance of the results has been debated. Objective: To establish a cheap, sensitive, and reliable assay for antibodies to 125|-|FN β, and to correlate levels of antibodies with clinical response to IFN β treatment. Methods: We established a radioimmunoprecipitation assay (RIPA) using 125|-|FN β. We tested NAB positive sera, healthy control sera, and serial samples of 33 IFN β-1b treated MS patients from the Vancouver cohort of the Berlex pivotal trial who had a high incidence of NABs. Results: We found that the RIPA was highly sensitive for the detection of antibodies to IFN β-1a and -1b, and that there was a strong correlation between reactivity of NAB positive sera for 125|-|FN β-1b and for 125|-|FN β-1a. The RIPA was more sensitive and consistent than the NAB. Moreover, there was a trend towards poorer MRI outcomes in RIPA positive patients, but not in NAB-positive patients. Conclusions: The RIPA assay is sensitive and easy to perform. It should be of value in assessing the clinical impact of IFN β antibodies, and its use could help target expensive INF β treatments to those who will respond best.

Cite

CITATION STYLE

APA

Lawrence, N., Oger, J., Aziz, T., Palace, J., & Vincent, A. (2003). A sensitive radioimmunoprecipitation assay for assessing the clinical relevance of antibodies to IFN β. Journal of Neurology, Neurosurgery and Psychiatry, 74(9), 1236–1239. https://doi.org/10.1136/jnnp.74.9.1236

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free